百濟神州(06160.HK)百澤安食管鱗狀細胞癌全球3期臨床試驗獲積極主要結果
百濟神州(06160.HK)公布,其用於評估抗PD-1抗體百澤安(替雷利珠單抗)對比研究者選擇的化療用於治療既往接受過全身療法的晚期不可切除,或轉移性食管鱗狀細胞癌(ESCC)的RATIONALE 302全球3期臨床試驗,達到總生存期(OS)這一主要終點。
試驗結果表明,針對意向治療人群(ITT),百澤安在總生存期中取得了具有統計和臨床意義的提高。百澤安的安全性數據與已知風險相符,未出現新的安全警示。公司計劃就RATIONALE 302試驗結果與全球範圍內多個監管部門開展溝通,並於接下來的一場醫療會議中公布數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.